55327-29-2

Usage

Uses

Used in Pharmaceutical Industry:
2-P-Tolyl-thiazole-4-carbaldehyde is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic properties. Its unique structure allows for the creation of molecules that can target specific biological pathways, thereby enhancing the effectiveness of medications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-P-Tolyl-thiazole-4-carbaldehyde is utilized as a precursor in the production of various agrochemicals, such as pesticides and herbicides. Its incorporation into these products can improve their efficacy in controlling pests and weeds, thus contributing to increased crop yields and agricultural productivity.
Used as a Laboratory Reagent:
2-P-Tolyl-thiazole-4-carbaldehyde also serves as a reagent in laboratory settings for the preparation of a broad spectrum of chemical compounds. Its versatility in organic synthesis makes it a valuable tool for researchers working on the development of new chemical entities and the improvement of existing ones.

InChI:InChI=1/C11H9NOS/c1-8-2-4-9(5-3-8)11-12-10(6-13)7-14-11/h2-7H,1H3

Upstream product

• 104-85-8 para-methylbenzonitrile 
• 36093-97-7 (2-p-tolylthiazol-4-yl)methanol 
• 2362-62-1 4-methylthiobenzamide 
• 534-07-6 1,3-Dichloroacetone 
• 132089-32-8 2-(4'-methylphenyl)-4-carbethoxythiazole 
• 35199-18-9 4-chloromethyl-2-(4-methyl-phenyl)-thiazole 
• 89152-41-0 4-(iodomethyl)-2-(p-tolyl)thiazole 

Downstream Products

• 21166-38-1 1-(2-p-tolyl-thiazol-4-yl)-ethanone 
• 138019-77-9 (Z)-1-(2-Hydroxy-phenyl)-3-(2-p-tolyl-thiazol-4-yl)-propenone 
• 116227-88-4 (Z)-1-Phenyl-3-(2-p-tolyl-thiazol-4-yl)-propenone 
• 108735-89-3 2-p-Tolyl-thiazole-4-carbaldehyde oxime 
• 174006-75-8 2-(p-tolyl)thiazole-4-carbonitrile 
• 174006-79-2 2-(p-tolyl)thiazole-4-carbothioamide 
• 116228-06-9 4-(2,5-Diphenyl-2H-pyrazol-3-yl)-2-p-tolyl-thiazole 
• 116227-96-4 4-(2,5-Diphenyl-3,4-dihydro-2H-pyrazol-3-yl)-2-p-tolyl-thiazole 
• 138019-87-1 3-Hydroxy-2-(2-p-tolyl-thiazol-4-yl)-chromen-4-one 
• 138019-82-6 Acetic acid 2-[(Z)-3-(2-p-tolyl-thiazol-4-yl)-acryloyl]-phenyl ester 
• 138019-92-8 Acetic acid 4-oxo-2-(2-p-tolyl-thiazol-4-yl)-4H-chromen-3-yl ester 
• 17228-99-8 2-(p-tolyl)thiazole-4-carboxylic acid 
• 64953-96-4 1-(2-p-tolylthiazol-4-yl)ethanol 
• 1585214-71-6 rac-2-(ethoxycarbonyl)-1-(2-p-tolylthiazol-4-yl)ethyl butanoate 

Relevant academic research and scientific papers

Synthesis of new 2-(thiazol-4-yl)thiazolidin-4-one derivatives as potential anti-mycobacterial agents

To search for potent antimycobacterial lead compounds, a new series of 3-substituted phenyl-2-(2-(substituted phenyl)thiazol-4-yl) thiazolidin-4-one (5a-t) derivatives have been synthesized by the condensation of 2-substituted phenyl thiazole-4-carbaldehy

Synthesis, Characterization, and Antimicrobial Screening of 4″-methyl-2,2″-diaryl-4,2′:4′,5″-terthiazole Derivatives

A series of novel 4″-methyl-2,2″-diaryl-4,2′:4′,5″-terthiazole (8a-p) derivatives has been synthesized and screened for antibacterial activity against four pathogenic bacteria, Escherichia coli, Pseudomonas flurescence, Staphylococcus aureus, and Bacillus subtilis. Among them, compounds 8a and 8j exhibited excellent antibacterial activity with minimum inhibitory concentration range of 1.0 to 5.3?μg/mL and compounds 8m and 8p exhibited moderate to good antibacterial activity with minimum inhibitory concentration range of 16.9 to 29.7?μg/mL against all tested strains. All the synthesized compounds were screened for their in vitro antifungal activity against Cocinida candida. Most of the compounds reported moderate antifungal activity. This study provides valuable directions to our ongoing endeavor of rationally designing more potent antimicrobial agent.

Synthesis, antitubercular and antimicrobial potential of some new thiazole substituted thiosemicarbazide derivatives

The increase in antibiotic resistance due to multiple factors has warranted the need for search of new compounds which are active against multidrug resistant pathogens. In this context a small focused library of thiosemicarbazide derivatives of 2-arylthiazole-4-carbaldehyde, 4-methyl-2-arylthiazole-5-carbaldehyde and 1-(4-methyl-2-arylthiazol-5-yl) ethanone, (5a–l) has been synthesized. The title compounds were screened for inhibitory activity against Mycobacterium tuberculosis H37Ra (ATCC 25177) and Mycobacterium bovis Bacille Calmette Guerin (ATCC 35743) strains. The synthesized compounds, 5a–l were further assayed for their cytotoxic activity against the two human cancer cell lines, HeLa and human colon carcinoma 116 cell lines and showed no significant cytotoxic activity against these two cell lines at the maximum concentration evaluated. Further, the synthesized compounds were found to have potential antibacterial activity against Gram-negative bacteria, Escherichia coli, Pseudomonas flurescence and Gram-positive bacteria, Staphylococcus aureus, Bacillus subtilis. Most of the synthesized compounds showed moderate activity against fungal strain Candida albicans. This study provides valuable directions to our ongoing endeavor of rationally designing more potent antimycobacterial agent.

Heterocycles 38. Biocatalytic synthesis of new heterocyclic mannich bases and derivatives

This paper describes the biocatalytic synthesis of new Mannich bases containing various heterocyclic rings (thiazole, furane, thiophene, pyridine) by applying the lipase catalyzed trimolecular condensation of the corresponding heterocyclic aldehydes with acetone and primary aromatic amines, in mild and eco-friendly reaction conditions. The obtained Mannich bases were acylated to their corresponding N-acetyl derivatives. All compounds were characterized by 1H-NMR, 13C-NMR and MS spectrometry.

Heterocycles 32. Efficient kinetic resolution of 1-(2-arylthiazol-4-yl) ethanols and their acetates using lipase B from Candida antarctica

In this paper we describe the chemoenzymatic synthesis of new enantiomerically enriched (R)- and (S)-1-(2-arylthiazol-4-yl)ethanols and their acetates by enzymatic enantioselective acetylation of the racemic alcohols rac-2a-d and by methanolysis of the corresponding racemic esters rac-3a-d mediated by lipase B from Candida antarctica (CaL-B) in non-aqueous media. In terms of stereoselectivity and activity, both procedures, acylation and alcoholysis, gave similar good results (50% conversion, E 〉 200). The absolute configuration of the kinetic resolution products was determined by a detailed 1H NMR study of the Mosher's derivatives of (S)-2b.

Synthesis, cytotoxicity assessment, and molecular docking of 4-substituted-2-p-tolylthiazole derivatives as probable c-Src and erb tyrosine kinase inhibitors

In the current project we focused on the synthesis of 4-Substituted-2-p- tolylthiazole derivatives. Cytotoxicity of synthesized compounds were evaluated against T47D breast cancer cell line and also all of the final compounds 3-7 were docked into the active site of c-Src and erb tyrosine kinases. Compound 4 was the most potent derivative in cytotoxicity assay (IC50 = 2.5 μg/mL) and it was also the most potent inhibitor of erb tyrosine kinase (Binding free energy: -10.18 kcal/mol).